Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial
Autore:
Alvarez, RD; Barnes, MN; Gomez-Navarro, J; Wang, MH; Strong, TV; Arafat, W; Arani, RB; Johnson, MR; Roberts, BL; Siegal, GP; Curiel, DT;
Indirizzi:
Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35233 USA Univ Alabama Birmingham AL USA 35233 & Gynecol, Birmingham, AL 35233 USA Univ Alabama, Gene Therapy Ctr, Birmingham, AL 35233 USA Univ Alabama Birmingham AL USA 35233 herapy Ctr, Birmingham, AL 35233 USA Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL 35233 USA Univ Alabama Birmingham AL USA 35233 & Toxicol, Birmingham, AL 35233 USA Univ Alabama, Biostat Unit, Birmingham, AL 35233 USA Univ Alabama Birmingham AL USA 35233 ostat Unit, Birmingham, AL 35233 USA Univ Alabama, Dept Pathol, Birmingham, AL 35233 USA Univ Alabama Birmingham AL USA 35233 ept Pathol, Birmingham, AL 35233 USA Univ Alabama, Dept Cell Biol, Birmingham, AL 35233 USA Univ Alabama Birmingham AL USA 35233 Cell Biol, Birmingham, AL 35233 USA Univ Alabama, Dept Surg, Birmingham, AL 35233 USA Univ Alabama BirminghamAL USA 35233 Dept Surg, Birmingham, AL 35233 USA Univ Alabama, Genzyme Corp, Birmingham, AL 35233 USA Univ Alabama Birmingham AL USA 35233 nzyme Corp, Birmingham, AL 35233 USA
Titolo Testata:
CLINICAL CANCER RESEARCH
fascicolo: 8, volume: 6, anno: 2000,
pagine: 3081 - 3087
SICI:
1078-0432(200008)6:8<3081:ACGTAU>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
OVARIAN-CANCER; INTRACELLULAR EXPRESSION; NASAL EPITHELIUM; CYSTIC-FIBROSIS; ERBB-2; VECTORS; SAFETY; TRANSFORMATION; ERADICATION; DELIVERY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Alvarez, RD Room 538 OHB,618 S 20th St, Birmingham, AL 35233 USA Room 538OHB,618 S 20th St Birmingham AL USA 35233 35233 USA
Citazione:
R.D. Alvarez et al., "A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial", CLIN CANC R, 6(8), 2000, pp. 3081-3087

Abstract

The purpose of this Phase I study was to determine the feasibility of using an anti-erbB-2-encoding adenovirus (Ad21) to treat erbB-2-overexpressing ovarian cancer. Recurrent ovarian cancer patients were treated i.p. with Ad21 in dosages ranging from 1 x 10(9) to 1 x 10(11) pfu, Patients were monitored after treatment for evidence of clinical toxicity and efficacy. Peritoneal aspirates and serum samples were obtained to assess for evidence of gene transfer/expression, for generation of wild-type vector, and antiadenoviral humoral response, Fifteen patients were treated per study specifications. Treatment-specific grade 1/2 fever was experienced by 9 of 15 (60%) patients. Other transient grade 1/2 constitutional, pain, and gastrointestinal symptoms were also experienced. No dose-limiting vector-related toxicity was experienced. Of 13 patients evaluable for response, 5 (38%) had stable disease and 8 (61%) had evidence of progressive disease. One patient with nonmeasurable disease normalized her CA125 at the 8-week evaluation, and one patient with nonmeasurable disease remained without clinical evidence of disease for 6 months after treatment. PCR analysis of peritoneal aspirates demonstrated the presence of Ad21 in 84.6%, 84.6%, and 61.6% of evaluable specimens at days 2, 14, and 56 after treatment, respectively. No wild-type virus was detected. Reverse transcription-PCR encoding gene in 10 of 14 evaluable patients at day 2, Five of six evaluable patients had an increase in antiadenovirus antibody titer, This study suggests that adenoviral-mediated gene therapy using an anti-erbB-2-directed intrabody is feasible in the context of human ovarian cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/05/20 alle ore 22:37:25